Central nervous system disorders represent a growing socio-economic burden at the global level, not only in terms of a number of patients but also in terms of high cost to healthcare systems. Biomarkers are quantifiable and measurable signs that can be used to monitor, diagnose and predict treatment response. They play an important role diagnostics and drug R&D. They are vital gears for developing more effective treatments, improving the quality of patient care and understanding disease mechanism. The detection of biomarkers for CNS disorders has expanded considerable interest within the industry due to the many unmet needs in current treatments and diagnostics.
The Global Central Nervous System (CNS) biomarker market is anticipated to grow from $ 3587 million in 2016 to $8756 million by 2025, at a CAGR of 10.49% between 2016 and 2025. The key concern that is majorly been faced by the developed as well as developing regions is the growing number of patients suffering from chronic diseases. Increase in a number of patients suffering from brain tumour has become one the major problems faced by the government of numerous countries. According to American Brain Tumor Association, around 78,000 individuals suffering from primary brain tumours are anticipated to be diagnosed in 2016.
In modern-day environment and availability of low priced high-calorie food is leading to gain of weight among people which are thereby causing diseases like diabetes and problems of blood pressure. Obesity is a rising health concern. According to WHO- World Health Organization, about more than 1.4 billion of adults are overweight over the globe and the prevalence is rising in the developing regions like Brazil and this prevalent is estimated to get worse.
The significant growth in the healthcare expenditure across geographies is been considered as the vital factor while allocating the market share across the regions. In 2015, around 16.7% of the GDP is projected to be spent as healthcare expenditure across the globe. Amongst it, CNS biomarkers is expected to account for a significant share in the healthcare expenditure owing to increasing prevalence of chronic diseases like cancer, Alzheimer etc. By 2025, about 19.3 million new cases of cancer are projected to be diagnosed at the global level.
Global Biomarkers market is largely fragmented. The market is filled with a huge number of companies, each of which is getting into specialized into a biomarker for specific purposes, such as CNS biomarker. Some of the top companies involved in CNS biomarker are Thermo Fisher, EKF diagnostic, Enzo Biochem and proteome sciences, out of these Thermo fishers holds a comparatively high share with respect to others as it has its global presence in each of the regions and has the high revenue for CNS biomarker (estimated).
Academic researchers, government agencies and pharmaceutical companies conduct numerous programs for the collection of clinical data. Hence, the development of a regulatory framework for sharing of the data with the authorities responsible for drugs development can help in overcoming the specified challenge. Application of biomarkers in personalized medicine is expected to be a game changer, owing to the rising need to develop treatments for the unique genes of patients. It is being projected that the patients suffering from chronic diseases such as cancers and tumours will slowly but assuredly adopt these medicines in the coming years which in turn will boost the CNS biomarkers market.
Read the full Report on "Global Central Nervous System (CNS) biomarker market "Global Central Nervous System (CNS) biomarker market" by Inkwood Research.
About Inkwood Research
Inkwood Research specializes in syndicated & customized research reports and consulting services. Market intelligence studies with relevant fact-based research are customized across industry verticals including technology, automotive, chemicals, materials, healthcare, and energy with objective comprehension acknowledging the business environments. Our geographical analysis comprises of North & South America, CEE, CIS, Middle East, Europe, Asia, and Africa.
Contact Us
+1 857-302-4704
